ARDD 2026 Highlights GLP-1 Longevity Data and New FDA Trial Pathways
Semaglutide projects 1.9 extra years of life, tirzepatide slows epigenetic aging clocks, and regulators outline an approvable path for longevity drugs.
Summary
The 2026 Aging Research and Drug Development conference, held at Harvard Medical School, brought together pharma giants, regulators, and scientists to advance longevity medicine. Highlights included Novo Nordisk modeling that projects semaglutide could add an average of 1.9 years of life, with the largest gains for younger starters. Eli Lilly shared epigenetic data from SURMOUNT-5 showing tirzepatide slowed all 15 biological age clocks over 72 weeks. ARPA-H outlined its $144 million PROSPR program to build trial infrastructure for aging therapeutics. The FDA indicated that the earliest approvable longevity trials will target age-related comorbidities or mortality, while surrogate endpoints are being validated to allow shorter studies. Government representation signaled growing policy momentum behind longevity and prevention.
Detailed Summary
The 2026 Aging Research and Drug Development (ARDD) conference relocated from Copenhagen to Boston, convening at Harvard Medical School and drawing an unusually senior mix of researchers, pharma executives, regulators, and government officials. The shift in venue brought longevity science to the epicenter of biomedical research, enabling contributions from luminaries including George Church and David Sinclair.
On the regulatory front, ARPA-H's Andrew Brack updated attendees on PROSPR, a $144 million, five-year initiative designed to build clinical trial infrastructure for aging therapeutics. The program's goal is to identify surrogate endpoints that regulators, physicians, payers, and patients can trust — enabling shorter trials that don't require mortality as the primary endpoint. FDA's Penzenstadler outlined an approvable framework: target populations experiencing age-related decline across multiple domains, use validated outcome measures, and collect intrinsic capacity assessments alongside hard endpoints until surrogate-to-survival linkages are firmly established.
Two of the biggest obesity drug makers presented compelling longevity data. Novo Nordisk's Nikolaj Roed shared SELECT trial modeling projecting that semaglutide could extend life by an average of 1.9 years, with greater gains for those who start treatment at a younger age. Eli Lilly's Kevin Duffin presented an epigenetic sub-study from SURMOUNT-5 in which all 15 biological age clocks measured after 72 weeks on tirzepatide showed less aging than the actual time elapsed, with results validated independently by TruDiagnostic.
Government engagement was a notable signal. Admiral Brian Christine, Assistant Secretary for Health, framed longevity and prevention as a central policy organizing principle, endorsing longer healthy lives as a national goal.
Caveats apply: the semaglutide longevity projection is modeled, not directly observed, and the tirzepatide epigenetic study involved only 15 subjects. Larger, longer trials are needed before clinical recommendations shift. Still, the convergence of regulatory clarity, industry investment, and government endorsement marks a meaningful inflection point for longevity medicine.
Key Findings
- Semaglutide modeled to add an average of 1.9 years of life, with bigger gains for younger starters.
- Tirzepatide slowed all 15 epigenetic aging clocks over 72 weeks in a 15-person SURMOUNT-5 sub-study.
- ARPA-H's $144M PROSPR program is building clinical trial infrastructure and surrogate endpoints for longevity drugs.
- FDA outlined an approvable longevity trial path: target age-related decline across cognition, frailty, hearing, and vision.
- Government officials framed longevity and prevention as a core national health policy priority.
Methodology
This is a conference report and editorial summary from Longevity.Technology, not a peer-reviewed study. Evidence cited includes SELECT trial modeling (Novo Nordisk), an epigenetic sub-study from SURMOUNT-5 (Eli Lilly, n=15), and regulatory statements from FDA and ARPA-H officials. Primary sources should be consulted for full data.
Study Limitations
The semaglutide lifespan projection is a model, not a direct trial observation, and requires prospective validation. The tirzepatide epigenetic sub-study involved only 15 participants, limiting statistical power. Conference-reported data has not undergone peer review and details may change upon full publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: